The FDA approved Viridian Therapeutics’ veligrotug for thyroid eye disease, with the drug to be marketed in the US as Lumvoa. The approval immediately sets up competition against Amgen’s Tepezza, which has dominated the indication. With pricing planned “in line with” Tepezza, the new entrant is positioned to capture share in a market driven by payer coverage decisions and patient-specific ophthalmic outcomes. For commercial and pipeline planners, the approval adds another option to a crowded segment where differentiation increasingly comes down to safety/tolerability, dosing convenience, and how real-world endpoints map to pivotal trial readouts.